Clinical care through telemedicine
CompuMed to Provide ECG Telemedicine and CardioGramKids Services to The Saban Free Clinic and School Health Centers System Wide
Los Angeles – February 2, 2011 – CompuMed, Inc. (NASDAQ OTC: CMPD) (http://www.compumed.net), a telemedicine and medical informatics company, has entered into an agreement with The Saban Free Clinic and school health centers to provide CompuMed’s electrocardiogram (ECG) telemedicine and CardioGramKids® services to the four community clinics and school health centers operated by the Clinic. Now in its 43rd year, The Saban Free Clinic (formerly The Los Angeles Free Clinic) provides nearly 90,000 patient visits annually to the uninsured, teens, and other vulnerable populations in the Greater Los Angeles area. CompuMed will provide the Clinic with the company’s ECG telemedicine equipment and with over-reads performed remotely by CompuMed’s cardiologists and pediatric cardiologists.
CompuMed will also provide The Saban Free Clinic with the company’s CardioGramKids Pediatric Screening services at the school health center the Clinic operates for the Los Angeles Unified School District at Hollywood High School. CompuMed’s CardioGramKids program was designed in tandem with pediatricians and other healthcare providers to provide ECG screening services to children and teenagers prior to taking psychotropic medications or participating in school or afterschool sports programs.
“We are grateful to CompuMed for significantly enhancing our ability to provide preventive cardiac health services to the Los Angeles community,” said Donzella Lee, M.P.H., Director of Operations at The Saban Free Clinic. “With CompuMed’s ECG telemedicine technology, the Clinic can provide patients with state-of-the-art electrocardiogram analysis services in a cost-effective and convenient manner,“ added Lee.
“We are pleased to be working with L.A.’s preeminent community clinic organization to enhance the delivery of preventive medicine to the children and adults of Los Angeles,” said CompuMed's lead cardiologist David M. Frisch, M.D., F.A.C.C. “By implementing CompuMed’s ECG telemedicine program system wide, The Saban Free Clinic is likely to prevent or minimize a large number of acute or long-term cardiac problems and save lives,” Dr. Frisch added.
“With the extension of our ECG telemedicine and CardioGramKids school health center programs into the major community clinic organizations, CompuMed continues to play a leading role in bringing ECG telemedicine to a wide variety of healthcare settings,” said CompuMed CEO Maurizio Vecchione. “It’s clear that the future of healthcare will rely heavily on the Internet and that companies in the telemedicine field like CompuMed are well positioned to prosper.”
CompuMed, Inc. (NASDAQ OTC: CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at www.compumed.net and follow at Twitter: @compumed.
Forward Looking Statements
Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.